Neisseria Meningitidis Patents (Class 424/250.1)
-
Publication number: 20120107339Abstract: Chimeric fHBPs that can elicit antibodies that are bactericidal for different fHBP variant strains of N. meningitidis, and methods of use, are provided.Type: ApplicationFiled: March 9, 2009Publication date: May 3, 2012Inventors: Dan M. Granoff, Peter Beernink, Jo Anne Welsch
-
Patent number: 8163296Abstract: GPC (gel permeation chromatography) and size exclusion chromatography with detection by multi-angle light scattering photometry (SEC-MALS) can be used to accurately measure molecular size and molar mass, respectively, of saccharide conjugates. The invention provides (a) a process for measuring the molecular size of a conjugated saccharide antigen within a sample, comprising a step of analyzing the sample by GPC, and (b) a process for measuring the molar mass of a conjugated saccharide antigen within a sample, comprising a step of analysing the sample by SEC-MALS.Type: GrantFiled: June 21, 2005Date of Patent: April 24, 2012Assignee: Novartis AGInventors: Giorgio Capannoli, Valeria Carinci, Sandro D'Ascenzi, Claudia Magagnoli
-
Publication number: 20120087976Abstract: The present invention relates to an aqueous adjuvant composition comprising a TLR-4 agonist and a saponin in a liposomal formulation and a non-ionic isotonicity agent having low salt concentrations.Type: ApplicationFiled: June 8, 2010Publication date: April 12, 2012Inventors: Veronique Henderickx, Dominique Ingrid Lemoine
-
Publication number: 20120070458Abstract: Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.Type: ApplicationFiled: March 24, 2010Publication date: March 22, 2012Applicant: NOVARTIS AGInventors: Mario Contorni, Lorenzo Tarli
-
Patent number: 8137680Abstract: The invention is based on methods that allow analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units. With a combination of saccharides from serogroups C, W135 and Y, the invention analyses sialic acid, glucose and galactose content. The glucose and galactose results are used to directly quantify saccharides from serogroups Y and W135, respectively, and the combined glucose and galactose content is subtracted from the sialic acid content to quantify saccharides from serogroup C. The three serogroups can thus be resolved even though their monosaccharide contents overlap. The three different monosaccharide analyses can be performed on the same material, without interference between the monosaccharides and without interference from any other saccharide materials in the composition (e.g. lyophilisation stabilisers).Type: GrantFiled: March 17, 2005Date of Patent: March 20, 2012Assignee: Novartis Vaccines and Diagnostics SRLInventors: Angela Bardotti, Daniela Proietti, Stefano Ricci
-
Publication number: 20120064119Abstract: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.Type: ApplicationFiled: November 17, 2011Publication date: March 15, 2012Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Francois-Xavier Jacques Berthet, Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20120064120Abstract: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.Type: ApplicationFiled: November 17, 2011Publication date: March 15, 2012Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Francois-Xavier Jacques Berthet, Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Patent number: 8129147Abstract: Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular biomass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified, and mechanically depolymerized by sonication. These purified polysaccharides were found in human clinical trials to be safe and immunogenic against meningococcal disease caused by N. meningitidis A, C, Y and W-135 serogroups in sub-Saharan Africa. In the preferred embodiment, the polysaccharides are conjugated to carrier proteins of diphtheria or tetanus toxiod to an average molecular size of 5100 to 9900 Daltons and provide broad spectrum protection to humans of all ages. Accelerated polysaccharide production and the efficacy of the resulting vaccine are demonstrated.Type: GrantFiled: July 12, 2010Date of Patent: March 6, 2012Inventor: Jeeri R Reddy
-
Patent number: 8128942Abstract: The present invention provides an immunogenic conjugate comprising biologically deacylated gram-negative bacterial moieties linked to D. discoideum proteinase 1, as well as novel subunits thereof, and methods of making and using the conjugates in vaccines to treat sepsis and other infectious complications.Type: GrantFiled: May 21, 2010Date of Patent: March 6, 2012Assignee: EndoBiologics, IncorporatedInventors: Gary L. Gustafson, Dan C. DeBorde
-
Publication number: 20120052092Abstract: The present invention relates to an immunogenic composition comprising at least one modified factor H binding protein, wherein the composition is capable of eliciting an immune response, when administered to a human or non-human animal; and associated compositions, uses and kits.Type: ApplicationFiled: October 26, 2009Publication date: March 1, 2012Applicant: IMPERIAL INNOVATIONS LIMITEDInventors: Rachel Exley, Christoph Tang, Susan M. Lea
-
Patent number: 8114960Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.Type: GrantFiled: June 28, 2010Date of Patent: February 14, 2012Assignee: Novartis AGInventors: Maria Beatrice Arico, Maurizio Comanducci, Cesira Galeotti, Vega Masignani, Marzia Monica Guiliani, Mariagrazia Pizza
-
Publication number: 20120027801Abstract: Various specific meningococcal proteins are disclosed. The invention provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by meningococcus, such as bacterial meningitis.Type: ApplicationFiled: October 13, 2011Publication date: February 2, 2012Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS AGInventors: Rino Rappuoli, Claire Fraser, Mariagrazia Pizza, Maria Scarselli, Davide Serruto, Hervé Tettelin
-
Patent number: 8101194Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.Type: GrantFiled: October 11, 2002Date of Patent: January 24, 2012Assignee: Wyeth LLCInventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
-
Publication number: 20120014991Abstract: Adjuvant for mucosal vaccines which modulates the effects of substances, including vaccine antigens in contact with mucosal body surfaces.Type: ApplicationFiled: September 23, 2011Publication date: January 19, 2012Applicant: BIOTEC PHARMACON ASAInventors: Jan RAA, Aud Katherine Herland BERSTAD, Hilde Sunove Waleur BAKKE, Bjorn HANEBERG, Inger LISE HAUGEN, Johan HOLST, Liba JANAKOVA, Gro Ellen KORSVOLD, Fredrik OFTUNG
-
Patent number: 8097260Abstract: The invention provides lipid A deficient mutant Neisseria meningitidis cells, pharmaceutical compositions incorporating such cells, and methods of using such cells.Type: GrantFiled: October 20, 2008Date of Patent: January 17, 2012Inventors: Michael A. Apicella, Deborah Post
-
Publication number: 20110300171Abstract: The invention relates to immunization against pathogenic bacterial strains which express or can express multiple factor H binding proteins. Certain aspects of the invention include vaccine compositions comprising at least two factor H binding proteins derived from a pathogenic bacterial strain which expresses multiple facto H binding proteins.Type: ApplicationFiled: September 14, 2009Publication date: December 8, 2011Applicants: HUMANITAS MIRASOLE S.P.A., NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.Inventors: Silvana Savino, John Donnelly, Rino Rappuoli, Mariagrazia Pizza, Barbara Bottazzi
-
Patent number: 8048433Abstract: The current invention provides new Gram negative polypeptides exhibiting lipid A 3-O-deacylase activity and are capable of modifying and/or detoxifying gram negative LPS. The present invention also provides Gram negative bacteria, Gram negative bacterial lipopolysaccharides (LPS) and compositions comprising LPS, which are provided with or treated with a 3-O-deacylase activity according to the invention and which may be used for pharmaceutical and/or veterinary purposes, in particular for the preparation of whole cell or acellular vaccines against pathogenic Gram negatives such as Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica.Type: GrantFiled: December 16, 2005Date of Patent: November 1, 2011Assignee: NVI Nederlands VaccininstituutInventors: Johannes Petrus Maria Tommassen, Peter André Van Der Ley, Jeroen Johannes Gerardus Geurtsen
-
Publication number: 20110262484Abstract: The present invention provides a method of immunizing a subject against a disease caused by Neisseria meningitidis, comprising administering to the subject a primer composition comprising a meningococcal outer membrane vesicle preparation, and a booster composition comprising a meningococcal protein antigen preparation. Vaccine combinations comprising primer and booster compositions and associated uses are also provided.Type: ApplicationFiled: September 4, 2009Publication date: October 27, 2011Applicant: Health Protection AgencyInventor: Ian Feavers
-
Publication number: 20110256180Abstract: Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of N. meningitidis, and methods of use of such proteins, are provided.Type: ApplicationFiled: March 29, 2011Publication date: October 20, 2011Inventors: PETER T. BEERNINK, DAN M. GRANOFF, ROLANDO PAJON FEYT
-
Patent number: 8039007Abstract: Various specific meningococcal proteins are disclosed. The invention provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by meningococcus, such as bacterial meningitis.Type: GrantFiled: June 29, 2007Date of Patent: October 18, 2011Assignees: J. Craig Venter Institute, Inc., Novartis AGInventors: Rino Rappuoli, Claire Fraser, Mariagrazia Pizza, Maria Scarselli, Davide Serruto, Hervé Tettelin
-
Publication number: 20110250223Abstract: Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH2-A-[-X-L-]n-B—COOH where X is an amino acid sequence, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than I. Proteins where each of the n —X— moieties shares sequence identity to each other —X— moiety, the protein is a ‘tandem protein’.Type: ApplicationFiled: June 13, 2011Publication date: October 13, 2011Applicant: NOVARTIS VACCINESS AND DIAGNOSTICSInventor: Mariagrazia PIZZA
-
Patent number: 8034358Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: GrantFiled: July 12, 2007Date of Patent: October 11, 2011Assignee: The University of QueeslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 8034349Abstract: Peptides that mimic the antigenic features of non human-cross-reactive protective epitopes of the MenB CP and nucleic acids encoding the peptide mimetics are disclosed. Antibodies elicited by these peptides do not bind to polysialic acid in host tissue and thus provide a safe and efficacious method for the treatment and/or prevention of Meningitis B.Type: GrantFiled: June 12, 2007Date of Patent: October 11, 2011Inventors: Giuseppe Teti, Franco Felici
-
Publication number: 20110229522Abstract: The invention provides compositions and methods for screening subjects at risk for contracting meningococcal disease and/or at risk for failing to elicit an immunogenic response to a vaccine against Neisseria meningitidis. The invention also provides kits for carrying out these screens, and improved vaccines against Neisseria meningitidis.Type: ApplicationFiled: September 4, 2009Publication date: September 22, 2011Applicant: University of MassachusettsInventors: Sanjay Ram, Tathagat Duttaray, Peter A. Rice, Lisa A. Lewis, Sunita Gulati
-
Patent number: 8007815Abstract: Combination vaccines for treating or preventing Neisseria meningitidis infection are described. The vaccines include Neisseria meningitidis serogroup B proteoliposomic vesicles and Neissera meningitidis serogroup C conjugated oligosaccharides.Type: GrantFiled: May 28, 1999Date of Patent: August 30, 2011Assignees: Novartis AG, Statens Institutt for FolkehelseInventors: Dan M. Granoff, Howard Raff, Ingeborg S. Aaberge, Bjorn Haneberg, Johan Holst
-
Patent number: 8003112Abstract: This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both S. pneumoniae and N. meningitides in a subject. In a preferred aspect, the immunogenic composition comprises covalently conjugated recombinant PsaA (“rPsaA”) from S. pneumoniae and capsular polysaccharide from N. meningitidis serogroup C. This disclosure further relates to methods for producing the immunogenic composition as well as methods for their use.Type: GrantFiled: April 16, 2009Date of Patent: August 23, 2011Assignees: Howard University, The United States of America as represented by the Secretary, Department of Health and Human Services; National Institutes of Health, Office of Technology TransferInventors: Stanley Shih-Peng Tai, Che-Hung Robert Lee
-
Publication number: 20110189215Abstract: The present invention relates to immunogenic compositions comprising neisserial blebs with upregulated levels of the NMB0964 antigens such that bacterial antibodies are generated against said antigen. Methods are also provided to upregulate expression through removal of the zinc repression mechanism of the cell or promoter or through removal of zinc from the culture medium.Type: ApplicationFiled: March 6, 2009Publication date: August 4, 2011Inventors: Martine Petronella Bos, Jan Poolman, Michiel Stork, Johannes Petrus Maria Tommassen, Vincent Weynants
-
Patent number: 7988979Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.Type: GrantFiled: January 11, 2008Date of Patent: August 2, 2011Assignees: J. Craig Venter Institute, Inc., Novartis AGInventors: Claire M. Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Maria Rosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulo Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, Craig Venter
-
Publication number: 20110171234Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising o more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and m preventing and treating Neisseria infections.Type: ApplicationFiled: February 14, 2011Publication date: July 14, 2011Applicant: Isis Innovation LimitedInventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Publication number: 20110159030Abstract: A composition for mucosal delivery, comprising two or more of the following: (a) an antigen which induces an immune response against Haemophilus influenzae; (b) an antigen which induces an immune response against Neisseria meningitidis; and (c) an antigen which induces an immune response against Streptococcus pneumoniae. The combination allows a single dose for immunising against three separate causes of a common disease, namely bacterial meningitis.Type: ApplicationFiled: March 4, 2011Publication date: June 30, 2011Inventor: Derek O'Hagan
-
Publication number: 20110150923Abstract: The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred. The invention also provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The use of chitosan and/or detoxified ADP-ribosylating toxin adjuvants enhances anti-meningococcal mucosal immune responses and can shift the Th1/Th2 bias of the responses.Type: ApplicationFiled: February 28, 2011Publication date: June 23, 2011Inventors: Giuseppe Del Giudice, Barbara Baudner, Derek O'Hagan
-
Publication number: 20110135679Abstract: The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) at least first and second adjuvants, wherein the first adjuvant comprises microparticles and wherein the second adjuvant comprises an imidazoquinoline compound, and (c) a pharmaceutically acceptable excipient, which compositions elicits an immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions and methods for using immunogenic compositions (e.g., for treatment), among other benefits.Type: ApplicationFiled: December 7, 2008Publication date: June 9, 2011Applicant: NOVARTIS AGInventors: Padma Malyala, Derek O'Hagan, Manmohan Singh
-
Patent number: 7947291Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.Type: GrantFiled: January 25, 2001Date of Patent: May 24, 2011Assignee: The University of QueenslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings
-
Publication number: 20110111017Abstract: The invention provides compositions featuring cationic liposome nucleic acid molecules complexed with pathogen derived antigen and methods of using such compositions for the treatment or prevention of an infectious disease. Other features and advantages of the invention will be apparent from the detailed description, and from the claims.Type: ApplicationFiled: February 24, 2009Publication date: May 12, 2011Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA,AS REP. BY THE SECRETARY,DEPT. OF HEALTH AND HUMAN SERVICInventors: Catharine M. Bosio, John T. Belisle, Jeffrey Fairman
-
Patent number: 7923018Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: GrantFiled: April 9, 2009Date of Patent: April 12, 2011Assignee: Isis Innovation Ltd.Inventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Anne Jaqueline Gidney, Andrew David Cox, James Clare Richards, Richard Edward Moxon
-
Patent number: 7910117Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: GrantFiled: July 24, 2009Date of Patent: March 22, 2011Assignee: Isis Innovation Ltd.Inventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Richard Edward Moxon
-
Publication number: 20110033500Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtB? is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions.Type: ApplicationFiled: October 21, 2010Publication date: February 10, 2011Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20110033491Abstract: A composition is provided comprising N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one antigenic component. The composition is suitable for use in vaccines and for treatment of infection, particularly meningococcal infection, demonstrating a broad spectrum of protection. A number of preferred antigenic components are described and include antigenic proteins and proteoglycans derived from N. meningitidis.Type: ApplicationFiled: April 12, 2010Publication date: February 10, 2011Inventors: Andrew Robinson, Margaret Robinson, Andrew Richard Gorringe, Michael John Hudson, Karen Margaret Reddin
-
Patent number: 7883876Abstract: Provided are methods for recombinant production of an O-acetyltransferase and methods for acetylating capsular polysaccharides, especially those of a Serogroup A Neisseria meningitidis using the recombinant O-acetyltransferase, and immunogenic compositions comprising the acetylated capsular polysaccharide.Type: GrantFiled: November 20, 2007Date of Patent: February 8, 2011Inventors: David S. Stephens, Seshu K. Gudlavalleti, Yih-Ling Tzeng, Anup K. Datta, Russell W. Carlson
-
Publication number: 20110020390Abstract: fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.Type: ApplicationFiled: February 20, 2009Publication date: January 27, 2011Inventors: Mariagrazia Pizza, Maria Scarselli, Marzia Monica Giuliani, Maria Arico, Rino Rappuoli
-
Publication number: 20110014226Abstract: A method to identify small molecules useful as therapeutics and/or vaccines to prevent, alleviate or ameliorate a pathogenic infection or an autoimmune disorder. The method can be used to screen small molecule test compounds for the ability to disrupt particular antigen-antibody interactions of interest. In one embodiment, the antigen is a pathogen-derived antigen and the antibody decreases or inhibits virulence of the pathogen when bound to the antigen (e.g., a neutralizing antibody, antibody with serum bactericidal activity, etc.). In another embodiment, the antigen is a self-antigen (autoantigen) and the antibody is an autoantibody that is known to be associated with a pathological condition (e.g., autoimmune disorder). Compounds that bind to the antigen or antibody disrupt binding can be used as therapeutics to decrease or inhibit the autoimmune disorder.Type: ApplicationFiled: March 17, 2009Publication date: January 20, 2011Inventors: Michael J. Caulfield, Michael D. Miller, Joseph G. Joyce, Paul D. Zuck, Krista L. Getty, Vadim Dudkin, Elizabeth A. Ottinger
-
Publication number: 20110014272Abstract: The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) of Neisseria meningitidis or a lipidated fragment thereof; or (ii) LPS and the lipidated TbpB of N. meningitidis or a lipidated fragment thereof are formulated together in liposomes; or (iii) LPS is conjugated with the lipidated TbpB of N. meningitidis or a lipidated fragment thereof; in order to obtain a preparation which does not contain OMVs and which is capable of inducing, after administration to a mammal, an anti-LPS immune response which is improved by comparison with the anti-LPS immune response observed after administration of the corresponding preparation in which the lipidated TbpB of N. meningitidis or a lipidated fragment thereof is omitted; as well as vaccine compositions thereof.Type: ApplicationFiled: May 14, 2010Publication date: January 20, 2011Applicant: SANOFI PASTEURInventors: Jean Haensler, Bruno Guy
-
Patent number: 7867498Abstract: The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years.Type: GrantFiled: March 25, 2009Date of Patent: January 11, 2011Assignee: Novartis AGInventors: Rino Rappuoli, Guido Grandi
-
Patent number: 7862827Abstract: Compositions comprising a first biological molecule from a Neisseria bacterium and a second biological molecule from a Neisseria bacterium. The term “biological molecule” includes proteins and nucleic acids. Preferred Neisseria species are N. meningitidis and N. gonorrhoeae.Type: GrantFiled: November 5, 2004Date of Patent: January 4, 2011Assignee: Novartis Vaccines and Diagnostics SRLInventors: Marzia Monica Giuliani, Mariagrazia Pizza, Rino Rappuoli
-
Publication number: 20100322958Abstract: Modified capsular saccharides comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia) or (Ib): —OX—Y (Ia) or —O—R1 (Ib) wherein X is C(O), S(O) or SO2; Y is NR1R2 or R3; R1 is C1-6 alkyl substituted with 1, 2 or 3 groups independently selected from hydroxyl, sulphydryl and amine; R2 is H or C1-6 alkyl; and R3 is C1-6 alkyl; processes for modifying a capsular saccharide with the blocking groups; saccharide-protein conjugates comprising the modified capsular saccharide; processes for making the saccharide-protein conjugates, pharmaceutical compositions comprising the modified capsular saccharides and/or saccharide-protein conjugates; and methods and uses of the same.Type: ApplicationFiled: January 11, 2008Publication date: December 23, 2010Inventors: Angela Bardotti, Alessandro Pianigiani, Francesco Berti, Paolo Costantino
-
Patent number: 7850973Abstract: The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of A? in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of A?, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to A?. In another aspect, the immunogenic fragment of A? is capable of elevating plasma A? levels. The immunogenic fragments comprise linear or multivalent peptides of A?. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.Type: GrantFiled: May 1, 2006Date of Patent: December 14, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Victor M. Garsky, Joseph G. Joyce, Paul M. Keller, Gene Kinney, Xiaoping Liang, John W. Shiver
-
Patent number: 7838014Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and Opc, and PorA and OpA and OpC. Alternatively, or in addition, lgtB? is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions.Type: GrantFiled: July 31, 2003Date of Patent: November 23, 2010Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Patent number: 7838015Abstract: A combination of CpG oligonucleotides and polymer microparticles is an extremely effective adjuvant for Neisserial antigens. The invention therefore provides a composition comprising: (a) a Neisserial antigen; (b) a CpG oligonucleotide; and (c) a biodegradable polymer microparticle.Type: GrantFiled: October 3, 2002Date of Patent: November 23, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Derek O'Hagan, Nicholas Valiante
-
Publication number: 20100291137Abstract: The present invention provides an isolated refolded NspA protein, and a method of preparing it.Type: ApplicationFiled: January 25, 2010Publication date: November 18, 2010Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Ralph Biemans, Martine Bos, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants, Johannes Petrus Maria Tommassen
-
Publication number: 20100285064Abstract: The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant.Type: ApplicationFiled: May 5, 2010Publication date: November 11, 2010Applicant: SERUM INSTITUTE OF INDIA LTD.Inventors: Suresh Sakharam Jadhav, Bhushan Patwardhan, Manish Gautam